SCHEMBL1639136

SCHEMBL1639136

O=C(C/C(=N/NC(=O)c1sc2ccccc2c1Cl)C(F)(F)F)c1cccs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.59
LMNA P02545 4/20 0.59
HTT P42858 4/20 0.59
ALDH1A1 P00352 9/20 0.59
MEN1 O00255 7/20 0.59
KMT2A Q03164 7/20 0.59
GAA P10253 5/20 0.59
KDM4E B2RXH2 4/20 0.59
CRHBP P24387 1/20 0.58
CRHR2 Q13324 1/20 0.58
OGG1 O15527 2/20 0.48
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPK1 P28482 1/20 0.44
POLB P06746 1/20 0.44
AGTR1 P30556 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639137 1.00 MAPT (0.59) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1638509 0.89 MAPT (0.57) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1638511 0.89 MAPT (0.57) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL12726693 0.82 MAPT (0.57) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1639215 0.82 MAPT (0.57) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1639211 0.82 MAPT (0.57) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1638496 0.80 MAPT (0.66) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1638499 0.80 MAPT (0.66) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1639205 0.79 MAPT (0.58) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL1639203 0.79 MAPT (0.58) MAPTLMNAHTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 MAPT 85/4885LMNA 2595/4885HTT 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.